Family-based analysis has revealed several loci for psoriasis and the locus, PSORS5, on chromosome 3q21 has been found in two independent studies. In this region, cystatin A (CSTA) encodes a skin barrier cystein protease inhibitor found in human sweat and it is over-expressed in psoriatic skin. Three CSTA markers at positions -190 (g.À190T4C), þ 162 (c.162T4C) and þ 344 (c.344C4T) were analysed in 107 unrelated patients and 216 matched controls. There was a significant trend for association with CSTA c.162T4C and psoriasis (odds ratio (OR) ¼ 3.45, Po0.001). Analysis of constructed haplotypes showed a highly significant association between disease and CSTA -190T/ þ 162C/ þ 344C (CSTA TCC) (P ¼ 10 À6 ). In independent study, a TDT analysis in 126 nuclear families confirmed the over-transmission of CSTA TCC (P ¼ 0.0001). The presence of statistical interaction between CSTA TCC haplotype and HLA-Cw6 at PSORS1 locus was detected by performing TDT analysis on CSTA haplotypes stratified by the presence or absence of the risk allele at HLA-Cw6 locus. To estimate the disease risk we employed conditional logistic regression on the family data. The CSTA TCC haplotype is only associated with psoriasis in those individuals carrying the risk allele at the HLA-Cw6 locus (OR ¼ 2.22, P ¼ 0.0004, 95% CI ¼ 1.42, 3.49). These results represent a major step towards the dissection of genetic factors involved in the pathogenesis of psoriasis.
Introduction
Psoriasis is a chronic inflammatory skin disorder characterized by epidermal hyper-proliferation, abnormal keratinocyte differentiation and premature desquamation of the stratum corneum. 1, 2 The prevalence differs with ethnic origin and geographical location and it ranges from 2 to 5% in the Caucasian population 3 to 0.1 to 0.3% in the Far East 4 and China. 5 Early studies proposed a multi-factorial mode of inheritance in which genetic and environmental factors jointly influence the onset and course of psoriasis. 6 A strong genetic component was confirmed by twin studies 7 and it has been further proposed that psoriasis is a disease involving gene -gene as well as gene -environment interactions exemplified by streptococcal infection, stress, smoking and physical trauma. 8 -10 During the past decade extensive research effort has focused on identifying psoriasis susceptibility loci, using linkage analysis on large family collections reviewed by Sagoo et al. 11 However, the only consistently replicated linkage in most of these studies was with the HLA region, (PSORS1), on chromosome 6p21.3 that contains the major histocompatibility complex. 12 In particular, it was well demonstrated that psoriasis is strongly associated with the human leucocyte-associated antigen HLA-Cw6 and individuals harboring this allele were found to have a 10-to 20-fold increased risk for developing psoriasis. 13 A recent study using recombinant haplotypes retained HLA-Cw6 as the risk allele conferring susceptibility to early onset psoriasis. 14 However, specific involvement of a gene in disease pathogenesis has not yet been established. PSORS5 is the candidate psoriasis susceptibility locus on chromosome 3q21 identified by linkage analysis in a Swedish family cohort 15, 16 (Supplementary Figure 1a) . There have been several candidate genes identified in this region, including those encoding two type-I membrane proteins of the immunoglobin superfamily, CD80 and CD86 antigens that were found to interact with CD28 to stimulate signals for Tcell activation as well as the integrin b-5 gene, which is associated with cell adhesion. Cystatin A, also known as stefin A, is another candidate gene in the 3q21 region. It encodes an 11 kDa protein (which corresponds to 98 amino acids). This is an acidic protein (pI 4.5) that is mainly located in the keratohyaline granules of the stratum granulosum and the cornified epithelium of the stratum corneum in the epidermis. 17 Cystatins are endogenous cysteine protease inhibitors that are found in several types of tissue and body fluid of mammals, plants and microorganisms and their main function is to protect tissues and cells from unfavourable proteolysis and to mediate the mechanism responsible for intra-or extracellular protein breakdown. 18 Cystatin A has been purified from human epidermis, hair shaft and nail as well as polymorphonuclear granulocytes, but it has also been detected in other tissues such as liver and spleen. 19, 20 The human CSTA gene is composed of three exons of 111, 102 and 226 bp in length, separated by two introns of 14 and 3.6 kbp, respectively 21, 22 (Supplementary Figure 1b) . In a recent study, two polymorphisms have been described within the CSTA gene, one in the promoter region (g.À190C4T) and another in exon 3 (c.344C4T), leading to the replacement of threonine by methionine at amino acid position 96 of the protein sequence (Supplementary Figure 1c) . However, genetic analysis of CSTA g. -190T4C in the CSTA promoter region and CSTA c.344C4T in CSTA exon 3 in a set of 148 nuclear families and 44 multi-affected families failed to show any association or linkage with psoriasis. 23 In view of the strong evidence for a role of cystatin A in the regulatory events of desquamation and its abnormal expression in psoriatic skin, 24, 25 we have sought to identify novel SNPs within the promoter and the coding regions of the CSTA gene by direct sequencing of PCR products. SNPs at positions g.À190T4C and c.344C4T have been confirmed in a British population and a new SNP in exon 2 at position þ 162 has been identified. The allelic distribution of CSTA g. -190T4C, c.162T4C and c.344C4T was determined in 107 unrelated patients and 216 matched controls. The frequency of each genetic variant and haplotypes constructed with the three SNPs in cases and controls were analysed. The results were replicated in an independent set of 126 nuclear families. Table 6 ). Amplification products were analysed on 1.5% agarose gels, stained with ethidium bromide (Sigma; 5 mg/ml) and visualised on a UV transilluminator. The desired bands were excised, passed through columns of glass wool (Sigma) and treated with chloroform and dimethyldichlorosilane, followed by ethanol precipitation. The purified DNA was sequenced using an EBI Prism 377 DNA sequencer (Applied Biosystems, Foster City, CA, USA). To detect possible polymorphisms, the resulting sequences were analysed using CLUSTALW (EBI; http://www.ebi.ac.uk/ CLUSTALW).
Materials and methods

Patients and controls
CSTA SNP genotyping
By means of using PCR-restriction fragment length polymorphism analysis (PCR-RFLP) with mutated primers introducing a restriction site for RFLP analysis dependent on the respective genotype, all available cases and control samples were genotyped for the following polymorphisms; CSTA g. -190T4C, c.162T4C and c.344C4T. Following PCR amplification using parameters described previously (4.2.2), RFLP analysis was performed in a volume of 30 ml containing 25 ml of the PCR product, 5 U of the selected enzyme and the corresponding manufacturer's buffer at the appropriate temperature overnight (New England Biolabs, Beverly, MA, USA). Digestion fragments were resolved on 3% agarose gels. In each reaction sequenceconfirmed samples were included as positive and negative controls. Genotyping was assessed independently by two investigators and in case of disagreement assays were repeated. For T-190C polymorphism, PCR using primers Pro-F (5 0 -GAAGACACATCCAGCCAAG-3 0 ) and Pro-Rmod (5 0 -GGAATTTGGAAGAAAGAGGGGTTGGAGGATGAAC C À188 A-3 0 ) created a Bsr I site by changing a T at position of À188 of the promoter sequence to G in the reverse primer. RFLP analysis was performed after incubation with 5 U of Bsr I at 65 1C overnight. Bsr I did not cut the À190T allele (300 bp) and produced bands of 263 and 37 bp for the À190C allele. In the case of the c.162T4C polymorphism, PCR with primers Ex2-Fmod (5 0 -GAAGAAAAAACAAATGA GACA 160 T-3 0 ) and Ex2-R (5 0 -TGAGAGTCCACCACTTG-3 0 ) generated an Nde I restriction site by changing a T at position þ 160 of the exon 2 sequence to A in the forward primer. Nde I digestion resulted in the generation of two fragments of 214 and 21 bp for the þ 162T allele, as against a single 235 bp fragment with the þ 162C allele. For the polymorphism, PCR using primers Ex3-F (5 0 -GACCTGT GGCTCTCTCAC-3 0 ) and Ex3-Rmod (5 0 -GAACACTTTGGGT ACATGCTGCTAAAAGCG 346 C-3 0 ) created a BstUI restriction enzyme site by changing the G at þ 346 on the CSTA sequence to a C on the reverse primer. BstUI did not cut the 344T allele (228 bp) and produced bands of 198 and 30 bp for 344C. HLA-Cw6 genotyping was performed as described previously. 26, 27 All PCR modified primers and conditions used for the cystatin A PCR-RFLP analysis in this study are summarised in (Supplementary Table 7 ).
Data analysis
Single SNP-based analysis Disease and control populations were compared non-parametrically. To investigate the possibility of a dose effect, ORs for the heterozygotes and homozygotes were calculated separately by comparing their risk with that for individuals homozygous for the alternative allele. As a dose effect was evident for the CSTA þ 162 marker, a w 2 -test for trend was carried out, weighted by the number of putative disease susceptibility alleles in each genotype group. For both CSTA-190 and CSTA þ 344 a w 2 analysis for carriage of the relevant allele was performed.
Linkage disequilibrium and haplotype analyses The standardized coefficient of disequilibrium (D') between all combinations of SNP pairs was assessed using the EMLD software (http://request.mdacc.tmc. edu/~qhuang/Software/pub.htm), which calculates pair-wise linkage disequilibrium (LD) based on SNP genotype data from unrelated individuals. In addition to analyses performed for each individual SNP, haplotypes across all three SNPs of the CSTA gene were also constructed and examined.
Haplotype analyses Haplotypes across all three SNPs of the CSTA gene were also constructed and analysed. The EHPLUS software 28 was used to generate group-wise haplotype frequencies (only haplotypes with frequencies over 5% were considered) for the case-control analysis. EHPLUS uses an expectation maximization (EM) algorithm to estimate haplotype frequencies and provides a w 2 -statistic for haplotype association with disease.
Family-based association analysis We tested for association between the CSTA haplotypes and psoriasis using the Transmit program (version 2.5). Transmit tests for association between haplotypes and disease by examining the transmission of haplotypes from parents to affected offspring. 29 A value of 5 for Var(O-E) is the threshold below which there is doubt about the appropriateness of the w 2 distribution under the null hypothesis. A Var(O-E) value less than 5 is viewed as unreliable. The CSTA haplotypes were tested for association with psoriasis in 126 psoriasis families. To examine the evidence for a statistical interaction, the same haplotype analysis was also performed after stratifying on the HLA-Cw6À/ þ genotype (presence or absence of the risk allele).
Conditional logistic regression We employed conditional logistic regression (CLR) on the family data to quantify the disease risk for the CSTA TCC haplotypes after 
Results
Three polymorphisms were detected by direct sequence analysis of PCR products, two of which were also found in a recent study 23 To confirm our findings, we assessed the association between the CSTA haplotypes and psoriasis by examining the transmission of haplotypes from parents to affected offspring, using the program Transmit on 126 psoriatic families (Table 3) . After adjustment for multiple testing, the T-C-C and T-T-C haplotypes provided significant evidence against the null hypothesis of no linkage with the disease (P ¼ 0.0001 and 0.0012, respectively). T-T-C is under-transmitted and T-C-C over-transmitted. Both haplotypes CSTA T-T-C and CSTA T-C-C were associated with the disease. We looked for statistical interactions between the psoriasis susceptibility loci at 3q21 and 6p21.3 by using Transmit to examine the linkage between cystatin A haplotypes after stratification based on presence/absence of the risk allele at HLA-Cw6. The results strongly support the presence of a statistical interaction as the linkage of the CSTA TCC and TTC haplotypes depends upon the genotype at the HLA-Cw6 locus ( Table 4 ). The TCC and TTC haplotypes only show evidence of linkage to psoriasis in the presence of at least one copy of the risk allele at the HLA-Cw6 locus. According to this analysis there appears to be a statistical interaction between alleles at the HLA-Cw6 locus and haplotypes at the CSTA locus. To assess the strength of the association between the CSTA TCC risk haplotype and psoriasis in the groups defined by presence or absence of the HLA-Cw6 risk allele, we performed CLR on the haplotypes in the family data by first generating pseudocontrols (see 'Materials and methods') in the two groups separately. The results shown in Table 5 indicate that the CSTA TCC haplotype only increases the risk of psoriasis in individuals carrying at least one copy of the risk allele at the HLA-Cw6 locus (OR ¼ 2.23, P ¼ 0.0002). The haplotype confers no increased risk to individuals who are HLA-Cw6 -(OR ¼ 1.07, P ¼ 0.791). This analysis supports our previous TDT analysis, indicating the presence of a statistical interaction between the CSTA haplotypes and the HLA-Cw6 alleles in the association with psoriasis.
Discussion
PSORS5, the susceptibility locus for psoriasis as well as other immune-mediated complex diseases, is located at the chromosome 3q21 region. This was defined by allelic association to microsatellite markers. 16 The PS-risk haplotype is a 5 SNP-marker haplotype identified by Hewett et al 31 using SNP markers and TDT analysis, within the 3q21 region; however no disease-causing function has been attributed to the gene (SLC12A8), including the intronic SNPs. 31 In this study we therefore focused on a gene (ie CSTA) located within the psoriasis susceptibility region on chromosome 3q21, but outside the 5-SNP marker haplotypes as previously defined. 31 33 Association of SLC12A8 with psoriasis is not conclusively established and needs further investigation. The evidence for a role of the CSTA in regulation of the skin barrier and thus, potential for involvement in psoriasis derives from the fact that cystatin A is identical to keratolinin, a cytosolic protein initially described as a substrate for epidermal transglutaminase. CSTA is now believed to be one of the precursors of the cornified cell envelope formed during terminal differentiation of keratinocytes, thereby suggesting that cystatin A expression is associated with keratinocyte differentiation. 34 While our study was in progress, an association analysis of cystatin A in a large Swedish family cohort showed no association with psoriasis. 23 On closer inspection, there are at least two good reasons why these contradictory results may have occurred. First, the authors did not study the CSTA c.162T4C polymorphism and power was insufficient to detect the association with CSTA c.162T4C-linked markers, such as CSTA g.À190T4C and/or CSTA c.344C4T. Second, the disease-causing mutation may be different in the two populations. Perhaps CSTA c.162T4C or a locus in LD with it in our sample, but another locus may be pathogenetic in the Swedish population. Another important issue is the interaction between PSORS1 and PSORS5. The disease risk seems to be higher for individuals who carry risk alleles at both CSTA and HLA-Cw6. However, the effect of CSTA appears to be dependent from that of HLA-Cw6 since the effect of both susceptibility and protective CSTA alleles is pronounced only in individuals who carry one or two copies of HLA-Cw6 (Table 4) . PSORS1 seems to interact with both PSORS4 35 and PSORS5 (this study), which could constitute a major step towards the dissection of genetic factors involved in the pathogenesis of psoriasis. Atopic dermatitis (AD) has also a major susceptibility locus on chromosome 3q21 36 and we recently showed that CSTA is associated with AD. 37 Interestingly, psoriasis and AD seem to share several susceptibility loci including the one on chromosome 3q21, 38 suggesting that CSTA could be the first common locus for psoriasis and AD identified so far. Our findings suggest that the synonymous CSTA SNP at position þ 162 is responsible for the most of the association. CSTA c.162T4C may be the pathogenetic mutation or lie in strong LD with the causative mutation. Until recently, it was widely accepted that synonymous mutations are selectively neutral and without an effect in gene expression and/or mRNA translation. However, this has proven to not be the case as evidence in favor for a role of synonymous mutations in mRNA stability, and regulation of gene expression comes from reports that small stretches of stem loops are important for the formation of stable elongation complexes as well as for termination of transcription. 39 -41 Also, in the case of the corneodesmosin gene, a synonymous mutation located in an RNA stability motif led to increased stability of the RNA transcript by diminishing the transcript affinity for a 39 kDa RNAbinding protein. 42 More recently, a silent SNP in the multi-drug resistance 1 gene has been reported to change 43 These results, taken together, provide strong evidence that a synonymous mutation in exon 2 of the human cystatin A gene is strongly associated with psoriasis in both case-control and family-based association studies and act independently from HLA-Cw6. The evidence for statistical interaction between these two loci is equivocal and needs further investigation. CSTA is a good candidate based in its expression and biological function, but CSTA TCC may just form part of an extended haplotype, which carries the true mutation on this region. Functional tests of this minimal risk haplotype should be performed to identify the true causative mutation (s).
